The Future of Pharmaceutical: Artificial Intelligence in Drug Discovery

Abstract

Artificial intelligence (AI), specifically machine learning and deep learning, has revolutionized drug discovery by significantly accelerating and mitigating risks throughout the pipeline, from target identification to clinical candidate selection. AI integrates and analyzes multidimensional data related to biology (genomics, proteomics, transcriptomics, and real-world clinical datasets) in order to clarify disease mechanisms, deduce causal gene-disease correlations, prioritize druggable targets, and uncover predictive biomarkers for precision medicine. In the earliest research, generative AI models (e.g., variational autoencoders, GANs, and diffusion models) combined with reliable protein structure prediction (AlphaFold2/3) allow for de novo drug design and virtual screening of billions of compounds. Graph neural networks and physics-informed neural networks improve polypharmacology profiling, binding affinity prediction, and ADMET property forecasting, significantly lowering attrition rates in hit-to-lead and lead optimization stages. Automation powered by AI simplifies retrosynthetic planning, high-throughput screening, and multi-objective strength, selection, and safety profile tuning. As a result, development schedules have been shortened from ten to fifteen years to possibly three to five years, all the while increasing success rates. Despite these developments, there are still issues that need to be resolved, such as the need for impartial, high-quality training data; the difficulty of interpreting deep learning models; ethical issues with privacy of data and algorithmic bias; and the possibility of overly optimistic extrapolated forecasts. For AI to be sustainably integrated into pharmaceutical development and research, these issues must be addressed through strong data collection, explainable artificial intelligence frameworks, and hybrid human–AI processes.